Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial-Reference-Cited by-同舟云学术

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

Published:2024-06 Issue:6 Volume:11 Page:e357-e368
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Mills Anthony M,Rizzardini Giuliano,Ramgopal Moti N,Osiyemi Olayemi O,Bogner Johannes R,Hagins Debbie P,Paredes Roger,Reynes Jacques,Rockstroh Jürgen K,Carr Andrew,Su Feng-Hsiu,Klopfer Stephanie O,Eves Karen,Plank Rebeca M,Correll Todd,Fox Michelle C

Funder

Merck Sharp and Dohme United Kingdom

Merck

Publisher

Elsevier BV

Reference26 articles.

1. HIV;Ghosn;Lancet,2018

2. Risks and benefits of reducing the number of drugs to treat HIV-1 infection;Cadiñanos;Expert Opin Drug Saf,2021

3. Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch?;Moreno;HIV Med,2019

4. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society—USA Panel;Gandhi;JAMA,2023

5. Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine;Boyle;Clin Pharmacokinet,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial;The Lancet HIV;2024-06

2. Is this the end of the road for daily islatravir 0·75 mg?;The Lancet HIV;2024-06